Processa Pharmaceuticals, Inc. ( (PCSA) ) has released its Q3 earnings. Here is a breakdown of the information Processa Pharmaceuticals, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies by modifying existing FDA-approved oncology drugs to improve their safety and efficacy. In its latest earnings report, Processa Pharmaceuticals reported a net loss of $10.2 million for the nine months ended September 30, 2025, compared to a $9.1 million loss for the same period in 2024. The company raised $10.6 million through public offerings and plans to use these funds for research and development and general corporate purposes. Processa is also exploring a cryptocurrency treasury strategy to diversify its capital base. Looking ahead, the company aims to continue its development of cancer therapies and explore strategic partnerships for its non-oncology drugs.